Goodwin: Leading the Charge in Life Sciences M&A
Deal News | Dec 06, 2024 | Goodwin
In recent months, Goodwin has emerged as a frontrunner in the life sciences M&A domain, adept at handling a variety of transactions globally since the third quarter of 2024. The firm has successfully advised on numerous deals involving strategic sales, carveouts, royalty acquisitions, and distressed transactions. Notable sell-side transactions include Biotheus's partnership with BioNTech and Collegium’s acquisition of Ironshore Therapeutics. On the buy-side, Ampersand Capital Partners completed the acquisition of Nektar Therapeutics’ business. Goodwin's prolific activity across these diverse deals highlights its strategic advisory strengths and positions it as a leader in the global life sciences M&A arena.
Sectors
- Life Sciences
- Mergers & Acquisitions
Geography
- Global – Goodwin's M&A activities span multiple jurisdictions globally, indicating its wide reach in the life sciences sector.
Industry
- Life Sciences – The article highlights Goodwin's involvement in numerous life sciences mergers and acquisitions, emphasizing its strong presence in this sector.
- Mergers & Acquisitions – The core subject of the article is Goodwin's activity in the M&A space, focusing on recent transactions in the life sciences sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Goodwin | Advisory Firm | Company | A global leader in mergers and acquisitions with a strong focus on life sciences transactions. |
| Biotheus | Target Company | Company | Entered into a strategic partnership with BioNTech. |
| BioNTech | Partner Company | Company | Partnered with Biotheus. |
| Collegium | Acquirer | Company | Completed the acquisition of Ironshore Therapeutics. |
| Ironshore Therapeutics | Target Company | Company | Acquired by Collegium. |
| Dr. Falk Pharma | Acquirer | Company | Acquired Kynos Therapeutics. |
| Kynos Therapeutics | Target Company | Company | Acquired by Dr. Falk Pharma. |
| Anika Therapeutics | Seller | Company | Sold Arthrosurface in a strategic sale. |
| Curon Biopharmaceutical | Seller | Company | Sold CN201 to Merck. |
| Merck | Acquirer | Company | Acquired CN201 from Curon Biopharmaceutical. |
| AlloVir | Participant in Merger | Company | Announced a merger with Kalaris Therapeutics. |
| Kalaris Therapeutics | Participant in Merger | Company | To merge with AlloVir. |
| Ampersand Capital Partners | Acquirer | Company | Completed the acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business. |